David Pelizzon Sells 250,000 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Pelizzon sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the transaction, the director directly owned 11,145,045 shares of the company’s stock, valued at $231,816,936. The trade was a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Alphatec Price Performance

ATEC traded down $0.46 during trading on Friday, reaching $19.74. 2,603,589 shares of the stock were exchanged, compared to its average volume of 2,130,456. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -17.47 and a beta of 1.17. Alphatec Holdings, Inc. has a 1 year low of $8.18 and a 1 year high of $21.16. The business’s 50 day moving average price is $15.99 and its two-hundred day moving average price is $13.82.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. The company’s quarterly revenue was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Stifel Nicolaus initiated coverage on Alphatec in a research report on Tuesday, October 28th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alphatec in a research report on Tuesday. Finally, Lake Street Capital set a $25.00 price target on Alphatec and gave the stock a “buy” rating in a report on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Trading of Alphatec

Several institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Alphatec during the 3rd quarter worth about $34,000. Osterweis Capital Management Inc. purchased a new stake in Alphatec during the second quarter worth approximately $37,000. Larson Financial Group LLC acquired a new stake in shares of Alphatec in the first quarter worth $54,000. Nisa Investment Advisors LLC raised its stake in shares of Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Alphatec in the 3rd quarter valued at $73,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.